Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis

Background: Increased blood brain barrier (BBB) permeability, CNS inflammation and neuroaxonal damage are pathological hallmarks in early multiple sclerosis (MS). Objective: To investigate the associations of neurofilament light chain (NfL) levels with measures of BBB integrity and central nervous system (CNS) inflammation in MS during the first demyelinating event. Methods: Blood and cerebrospinal fluid (CSF) were obtained from 142 MS (McDonald 2017) treatment-naive patients from the SET study (63% female; age: 29.7 ± 7.9 years) following the disease onset. NfL, albumin, immunoglobulin G (IgG), and immunoglobulin M (IgM) levels were measured in CSF and blood samples. Albumin quotient was computed as a marker of BBB integrity. Immune cell subset counts in CSF were measured using flow cytometry. MS risk factors, such as Human leukocyte antigen DRB1 locus gene (HLA DRB1)*1501, anti-Epstein–Barr virus (EBV) antibodies, and 25-hydroxy vitamin D3, were also measured. Results: Higher serum NfL (sNfL) levels were associated with higher albumin quotient (p < 0.001), CSF CD80+ (p = 0.012), and CD80+ CD19+ (p = 0.015) cell frequency. sNfL levels were also associated with contrast-enhancing and T2 lesions on brain magnetic resonance imaging (MRI; all p ⩽ 0.001). Albumin quotient was not associated with any of the MS risk factors assessed. sNfL levels were associated with anti-EBV viral capsid antigen (VCA) IgG levels (p = 0.0026). Conclusion: sNfL levels during the first demyelinating event of MS are associated with greater impairment of BBB integrity, immune cell extravasation, and brain lesion activity on MRI.

[1]  L. Kappos,et al.  Blood neurofilament light chain as a biomarker of MS disease activity and treatment response , 2019, Neurology.

[2]  K. Blennow,et al.  Vitamin D supplementation and neurofilament light chain in multiple sclerosis , 2018, Acta neurologica Scandinavica.

[3]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[4]  K. Blennow,et al.  Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis , 2018, Journal of Neuroinflammation.

[5]  Ludwig Kappos,et al.  Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis , 2018, Brain : a journal of neurology.

[6]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[7]  K. Blennow,et al.  Monitoring disease activity in multiple sclerosis using serum neurofilament light protein , 2017, Neurology.

[8]  M. Dwyer,et al.  A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long‐Term Comparative Study , 2017, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[9]  G. DeLuca,et al.  Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  K. Blennow,et al.  Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability , 2017, Brain Research.

[11]  Ludwig Kappos,et al.  Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.

[12]  J. Salzer,et al.  Vitamin D and axonal injury in multiple sclerosis , 2016, Multiple sclerosis.

[13]  M. Ramanathan,et al.  Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later , 2016, Multiple sclerosis.

[14]  M. Sormani,et al.  Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.

[15]  M. Ramanathan,et al.  Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients[S] , 2015, Journal of Lipid Research.

[16]  G. Ortiz,et al.  Role of the blood-brain barrier in multiple sclerosis. , 2014, Archives of medical research.

[17]  A. Vandamme,et al.  CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis , 2014, Journal of Neuroinflammation.

[18]  M. Dwyer,et al.  Thalamic atrophy is associated with development of clinically definite multiple sclerosis. , 2013, Radiology.

[19]  M. Ramanathan,et al.  Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study , 2013, PloS one.

[20]  Dana Horakova,et al.  Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.

[21]  S. Amor,et al.  Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis , 2012, Glia.

[22]  M. De Paschale,et al.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. , 2012, World journal of virology.

[23]  F. Hanefeld,et al.  Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid , 2009, Multiple sclerosis.

[24]  M. Barnett,et al.  The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion , 2006, Multiple sclerosis.

[25]  Gavin Giovannoni,et al.  Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. , 2005, Archives of neurology.

[26]  A. Minagar,et al.  Pathogenesis of brain and spinal cord atrophy in multiple sclerosis. , 2004 .

[27]  Alireza Minagar,et al.  Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.

[28]  B. Trapp,et al.  Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences , 2001, Current opinion in neurology.

[29]  H. Wada Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. , 1998, Internal medicine.

[30]  A. Reder,et al.  Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. , 1997, The Journal of clinical investigation.

[31]  J. Benjamins,et al.  Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. , 1989, Laboratory investigation; a journal of technical methods and pathology.